Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan

Documents similaires

• Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
  par: Yu‐Nan Huang, et autres
  Publié: (2024)
• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  par: David C. Klonoff, et autres
  Publié: (2024)
• Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
  par: Darren Lau, et autres
  Publié: (2024)
• Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
  par: Fu‐Shun Yen, et autres
  Publié: (2025)
• A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
  par: Filip K. Knop, et autres
  Publié: (2024)